<DOC>
	<DOC>NCT01002092</DOC>
	<brief_summary>Purpose: This study will assess the safety and efficacy of Endostar combined with chemotherapy in osteosarcoma patients.</brief_summary>
	<brief_title>A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<criteria>Patients with histologically confirmed osteosarcoma, who have no evidence of metastasis At least one measurable lesion Life expectancy &gt; 3 months ECOG performance status 02 Adequate hematologic, cardiac, renal, and hepatic function Patients with prior chemotherapy should have at least 4 weeks clearance period before entering this study Evidence of metastasis Serious infection Evidence of bleeding diathesis Significant cardiovascular disease Pregnant or lactating woman Allergic to E.coli preparation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Osteosarcoma</keyword>
	<keyword>Endostar</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>